dulxparx {ICEinfer} | R Documentation |
The data are from two arms of a double-blind clinical trial in which 91 patients were randomized to the SNRI duloxetine 80 mg/d (40 mg BID) and 87 patients were randomized to the SSRI paroxetine 20 mg/d for treatment of major depressive disorder (MDD). Missing-data- imputation and sensitivity-analyses were needed to make meaningful cost-effectiveness comparisons in this study.
data(dulxparx)
A data frame of 3 variables on 178 patients; no NAs.
Copley-Merriman C, Egbuonu-Davis L, Kotsanos JG, Conforti P, Franson T, Gordon G. Clinical economics: a method for prospective health resource data collection. Pharmacoeconomics 1992; 1(5): 370–376.
Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallincrodt C, Demitrack MA. Duloxetine in the treatment of depression - A double-blind, placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004; 24: 389–399.
Hamilton M. Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology 1967; 6: 278–296.
Obenchain RL, Robinson RL, Swindle RW. Cost-effectiveness inferences from bootstrap quadrant confidence levels: three degrees of dominance. J Biopharm Stat 2005; 15(3): 419–436.
Obenchain RL. ICEinR.pdf ../R_HOME/library/ICEinfer 2009; 30 pages.
Schoenbaum M, Unutzer J, Sherbourne C, Duan N, Rubenstein LV, Miranda J, Meredith LS, Carney MF, Wells K. Cost-effectiveness of practice-initiated quality improvement for depression: results of a randomized controlled trial. JAMA 2001; 286(11): 1325–1330.
# Demo of ICEinfer functionality on the dulxparx dataset... demo(dulxparx)